ClinicalTrials.gg
RecruitingNCT06263231INVINCIBLE-3Updated Nov 17, 2026

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

A Phase 3 interventional study of INT230-6 and Eribulin in Sarcoma,Soft Tissue, sponsored by Intensity Therapeutics, Inc.. Recruiting at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Intensity Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.
Updated Nov 17, 2026Site recruiting status changedSponsor changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
333
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Planned enrollment
32nd of 800
333 · median 35
Started
2024
with 26 others
Phase 3
38 of 958
2 open now
Primary completion
2027-12
later than 134 of 240 live
Registered
862nd of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 32nd largest by planned enrollment of the 800 interventional ones that give a count, is one of 27 that started in 2024, is one of 38 in phase 3, reaches primary completion later than 134 of the 240 other live ones, and was the 862nd registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.

03

Conditions studied

  • Sarcoma,Soft Tissue

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is of any sex and must be ≥ 18 years old and provide written to participate in the study.

    Type of Participant and Disease Characteristics

  2. proven, unresectable, locally advanced, or Soft Tissue Sarcoma (STS) only of the following subtypes: liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), leiomyosarcoma, and undifferentiated pleomorphic sarcoma. Participant must have a pathology report indicating the diagnosis of their STS.
  3. Participant must have received at least 1 for a STS and must have progressed following anthracycline-based or alternative standard therapies, except if medically or refused by participant. Participant cannot have received more than 2 prior regiments for unresectable, locally advanced or metastatic STS.
  4. Participant must have per 1.1 criteria.
  5. Participant must have at least 1 target tumor suitable for injection using routine image guidance ≥ 2 cm measurable by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).
  6. Participant must have an (ECOG) performance status of 0, 1 or 2 (see Section 11.7).
  7. Participant must have adequate organ function as defined by screening laboratory values that must meet the following criteria:

    1. Neutrophils ≥ 1500/μL (≥ 1.5× 109/L).
    2. (PT), and International Normalized Ratio (INR) ≤ 1.5× (ULN), ≥ 100,000/μL (≥ 10× 109/L); ≥ 9 g/dL. Criteria must be met without erythropoietin dependency and without packed red blood cell transfusion within the last 2 weeks.
    3. Creatinine within normal range; or calculated > 50 mL/min by the Cockcroft-Gault equation.
    4. (ALT) Serum Glutamic-Oxaloacetic Transaminase (SGOT)/ Aspartate Aminotransferase (AST) Serum Glutamic-Pyruvic Transaminase (SGPT) ≤ 2.5× ULN without, and ≤ 5× ULN with hepatic metastases.
    5. ≤ 1.5× ULN (except participants with Gilbert's syndrome, who must have total bilirubin \< 3.0 mg/dL [\< 52 µmol/L]).
    6. Creatine phosphokinase \< 2.5× ULN Sex and /Barrier Requirements
  8. A female participant is eligible to participate if she is not pregnant (as demonstrated by pregnancy testing prior to each treatment; performed at least monthly), not breastfeeding, and at least 1 of the following conditions applies:

    1. Not a Woman of (WOCBP). Women of non-childbearing potential are defined as women with functioning ovaries with a documented history of tubal ligation or hysterectomy or females who are post menopausal, as defined by 12 months of spontaneous amenorrhea with an appropriate clinical profile, e.g., age appropriate, > 45 years, in the absence of hormone replacement therapy. In questionable cases, a blood sample for Follicle Stimulating Hormone (FSH) and estradiol will be obtained to confirm childbearing potential.
    2. A WOCBP who may become pregnant or who is sexually active with a partner and who could become pregnant agrees to use a highly effective form of contraception during the study and for at least 7 months after the end of study intervention (see Section 11.5.2 for highly effective methods of contraception).
  9. Male participants with female partners of childbearing potential must agree to use contraception and refrain from sperm donation during the study and for 6 months after the end of study intervention (Section 11.5.2.2).

Exclusion criteria

Exclusion Criteria:

:

  1. Adult participants who lack capacity to consent without a legally authorized representative will be excluded from this study.

    Medical Conditions:

  2. Prior primary or brain or meningeal tumors unless clinically and radiographically stable as well as off- therapy for at least 2 months.
  3. History of severe reactions to US SOC agents and vinblastine or cisplatin or other products of the same class and their .
  4. proven, unresectable, locally advanced or metastatic STS subtypes other than those specified, for example excluded subtypes include liposarcoma (well differentiated), desmoid or dermatofibrosarcoma protuberans.
  5. Other prior , except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the participant has been disease-free for at least 2 years.
  6. Underlying medical condition that, in the investigator's opinion, will make the administration of study intervention hazardous or obscure the interpretation of toxicity determination or Adverse Events (AEs).
  7. Concurrent medical condition requiring the use of medications, or systemic corticosteroids (topical steroids are permitted); systemic corticosteroids must be discontinued at least 4 weeks prior to dosing.

    Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if the participant is on a stable dose. Non-absorbed intra-articular steroid injections will be permitted. Use of steroids as prophylactic treatment for participants with contrast allergies to diagnostic imaging contrast dyes will be permitted.

  8. Participants who require uninterrupted anticoagulants of any type or is on daily aspirin therapy or NSAIDS.
  9. Known significant chronic liver disease, such as cirrhosis or active hepatitis (potential participants who test positive for surface antigen or antibodies are allowed provided they do not have active disease requiring antiviral therapy).
  10. Myocardial infarction within 6 months before enrollment, Class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, pericardial disease or electrocardiographic evidence of acute ischemic or active conduction system abnormalities.
  11. Uncontrolled intercurrent illness including, but not limited to, poorly controlled hypertension or diabetes, ongoing active infection or psychiatric illness/social situation that may potentially impair the participant's compliance with study procedures.
  12. Participants with a interval (QTc) of >450 ms for men and >470 ms for women, or with a history of serum electrolyte abnormalities known to prolong the QT interval such hypocalcemia, hypokalemia, and hypomagnesemia, or a family or personal history of congenital long QT syndrome.
  13. Participants actively receiving therapy with strong Cytochrome P450 3A4 isoenzyme () inhibitors (e.g, erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil).
  14. Participants actively receiving therapy with medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study intervention.

    Prior/Concomitant Therapy

  15. Prior chemotherapy or immunotherapy (tumor vaccine, cytokine or growth factor given to control the cancer: systemic or IT) must have been completed at least 4 weeks prior to dosing (with the exception of kinase inhibitors or other short half-life drugs, a 2-week washout is acceptable prior to treatment) and all AEs have either returned to baseline or stabilized. Note: participants who have received prior platinum therapy are eligible irrespective of their response. If participant had received one of the 3 US SOC study regimens prior to enrollment, that previous US SOC cannot be assigned in this study.
  16. Prior systemic radiation therapy (IV, intrahepatic or oral) completed at least 4 weeks prior to study intervention administration. Prior focal radiotherapy completed at least 2 weeks prior to study intervention administration.

    a. Prior major treatment-related surgery completed at least 4 weeks prior to study intervention administration.

  17. Use of other drugs (drugs not marketed for any indication) within 28 days prior to study intervention administration.
  18. Received a within 6 weeks of first dose of study intervention.
  19. Received a Coronavirus Disease (COVID-19) vaccine less than 1 week prior to dosing (Cycle 1/Day 1) and/or during the study received a COVID-19 vaccine or booster less than 3 weeks ahead of a tumor assessment.

    Other Exclusion Criteria

  20. Pregnancy Exclusion: A who has a positive pregnancy test (e.g., within 72 hours) prior to treatment. If a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
333 participants (estimated)

Study arms

  • Experimental
    INT230-6 Monotherapy

    INT230-6 administered intratumorally. Participants will be dosed every 2 weeks (± 2 days) for up to a total of 5 treatment sessions (e.g., Days 1, 15, 29, 43 and 57). Once the participant has completed the treatment phase, they will continue into a 22-month maintenance phase, where investigators may inject new lesions or previously injected lesions with up to 175 mL of INT230-6 every 12 weeks (Q12W) ± 14 days. Dose volume in a session is dependent on the participants presenting tumor burden.

    Drug: INT230-6

  • Active comparator
    US Standard of Care

    Participants in this arm may receive any of the following depending on soft tissue sarcoma (STS) subtype and PI preference: * Pazopanib: 800 mg PO every day until clinical deterioration or disease progression * Trabectedin: 1.5 mg/m2 body surface area as 24-hour IV infusion every 3 weeks until clinical deterioration or disease progression * Eribulin: Non- European Union (EU) sites: 1.4 mg/m2 eribulin mesylate body surface area IV on Days 1 and 8 every 3 weeks until clinical deterioration or disease progression EU sites: 1.23 mg/m2 (free base) body surface area IV on Days 1 and 8 every 3 weeks until clinical deterioration or disease progression

    Drug: Eribulin · Drug: Trabectedin · Drug: Pazopanib

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    To compare OS for INT230-6 vs US Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.

    Time frame: From date of randomization until the documented date of death from any cause for a period of up to 2 years, unless superiority is demonstrated sooner or 80% of deaths during the study period.

Secondary outcomes

  1. Overall Survival (OS) For INT230-6 Compared to OS for Standard of Care (SOC) for Participants with leiomyosarcoma

    To compare OS for INT230-6 vs US SOC in participants with leiomyosarcoma

    Time frame: From date of randomization until the documented date of death from any cause for a period of up to 2 years, unless superiority is demonstrated sooner or 80% of deaths during the study period.

  2. Overall Survival (OS) For INT230-6 Compared to OS for Standard of Care (SOC) for Participants with liposarcoma

    To compare OS for INT230-6 vs US SOC in participants with liposarcoma

    Time frame: From date of randomization until the documented date of death from any cause for a period of up to 2 years, unless superiority is demonstrated sooner or 80% of deaths during the study period.

07

Study locations

10 of 20 sites recruiting
  • Mayo Clinic - Arizona
    Phoenix, Arizona 85054, United States
    Recruiting
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
    Active, not recruiting

    Not enrolling at this site.

  • University of California Los Angeles (UCLA) - Santa Monica Cancer Care
    Santa Monica, California 90404, United States
    Recruiting
  • Yale School of Medicine - Smilow Cancer Hospital - Yale - New Haven Hospital Location
    New Haven, Connecticut 06519, United States
    Active, not recruiting

    Not enrolling at this site.

  • Mayo Clinic - Florida
    Jacksonville, Florida 32224, United States
    Recruiting
    • Steven Attia, D.O. · Contact904-944-3301
    • Steven Attia, D.O. · Principal investigator
  • Profound Research LLC
    Farmington Hills, Michigan 48333, United States
    Active, not recruiting

    Not enrolling at this site.

  • Mayo Clinic - Rochester I
    Rochester, Minnesota 55902, United States
    Recruiting
    • Scott Okuno, MD · ContactOkuno.scott@Mayo.edu · (507) 284-2511
    • Scott Okuno, MD · Principal investigator
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
    Recruiting
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
    Recruiting
  • The James Cancer Hospital and Solove Research Institute
    Columbus, Ohio 43210, United States
    Recruiting
  • University of Pennsylvania - Abramson Cancer Center
    Philadelphia, Pennsylvania 19106, United States
    Recruiting
  • Temple University - Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
    Recruiting
    • David Brown · ContactDavid.Brown2@fccc.edu · 215-728-2769
    • Margaret Von Mehren, MD · Principal investigator
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Active, not recruiting

    Not enrolling at this site.

  • Centre Leon Berard
    Lyon, 69008, France
    Active, not recruiting

    Not enrolling at this site.

  • Helios Klinikum Bad Saarow
    Bad Saarow, 15526, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Universitäres Krebszentrum (UCCL)
    Leipzig, 04103, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Hospital Universitari Vall Hebron
    Barcelona, 08740, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Centro Integral Oncologico Clara Campal (HM CIOCC)
    Madrid, 28050, Spain
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Publications

  • Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH, Brennan MF. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999 May;229(5):602-10; discussion 610-2. doi: 10.1097/00000658-199905000-00002. PubMed 10235518 ↗
  • Beaver JA, Hazarika M, Mulkey F, Mushti S, Chen H, He K, Sridhara R, Goldberg KB, Chuk MK, Chi DC, Chang J, Barone A, Balasubramaniam S, Blumenthal GM, Keegan P, Pazdur R, Theoret MR. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2018 Feb;19(2):229-239. doi: 10.1016/S1470-2045(17)30846-X. Epub 2018 Jan 18. PubMed 29361469 ↗
  • Bender LH, Abbate F, Walters IB. Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models. Int J Mol Sci. 2020 Jun 24;21(12):4493. doi: 10.3390/ijms21124493. PubMed 32599852 ↗
  • Bloom AC, Bender LH, Tiwary S, Pasquet L, Clark K, Jiang T, Xia Z, Morales-Kastresana A, Jones JC, Walters I, Terabe M, Berzofsky JA. Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. Oncoimmunology. 2019 Jul 16;8(10):e1625687. doi: 10.1080/2162402X.2019.1625687. eCollection 2019. PubMed 31646070 ↗
  • Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schoffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D. Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database. Ann Oncol. 2014 Jun;25(6):1222-8. doi: 10.1093/annonc/mdu108. Epub 2014 Mar 7. PubMed 24608201 ↗
  • Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014 Oct 5;740:364-78. doi: 10.1016/j.ejphar.2014.07.025. Epub 2014 Jul 21. PubMed 25058905 ↗
  • Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14. PubMed 26371143 ↗
  • Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, De Alava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krakorova DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schoffski P, Sleijfer S, Strauss D, Strauss S, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Casali PG, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021 Nov;32(11):1348-1365. doi: 10.1016/j.annonc.2021.07.006. Epub 2021 Jul 22. No abstract available. PubMed 34303806 ↗
  • Jones RL, Maki RG, Patel SR, Wang G, McGowan TA, Shalaby WS, Knoblauch RE, von Mehren M, Demetri GD. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Dec 15;125(24):4435-4441. doi: 10.1002/cncr.32462. Epub 2019 Sep 10. PubMed 31503332 ↗
  • Lammers T, Peschke P, Kuhnlein R, Subr V, Ulbrich K, Huber P, Hennink W, Storm G. Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia. 2006 Oct;8(10):788-95. doi: 10.1593/neo.06436. PubMed 17032495 ↗
  • Meyer M, Seetharam M. First-Line Therapy for Metastatic Soft Tissue Sarcoma. Curr Treat Options Oncol. 2019 Jan 24;20(1):6. doi: 10.1007/s11864-019-0606-9. PubMed 30675651 ↗
  • von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Pollack SM, Poppe M, Riedel RF, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Hang LE, Sundar H, Bergman MA. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Jul;20(7):815-833. doi: 10.6004/jnccn.2022.0035. PubMed 35830886 ↗
  • Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res. 2007 Sep 1;67(17):7941-4. doi: 10.1158/0008-5472.CAN-07-1622. PubMed 17804698 ↗
  • Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available. PubMed 7165009 ↗
  • Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol. 2001 Nov;74(887):983-6. doi: 10.1259/bjr.74.887.740983. No abstract available. PubMed 11709461 ↗
  • Phillips E, Jones RL, Huang P, Digklia A. Efficacy of Eribulin in Soft Tissue Sarcomas. Front Pharmacol. 2022 Mar 30;13:869754. doi: 10.3389/fphar.2022.869754. eCollection 2022. PubMed 35444542 ↗
  • Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, Casali PG; RARECARE Working Group. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013 Feb;49(3):684-95. doi: 10.1016/j.ejca.2012.09.011. Epub 2012 Oct 15. PubMed 23079473 ↗
  • Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Sep 1;34(25):2969-79. doi: 10.1200/JCO.2016.66.9861. Epub 2016 Jun 27. PubMed 27354481 ↗
  • Sok M, Sentjurc M, Schara M, Stare J, Rott T. Cell membrane fluidity and prognosis of lung cancer. Ann Thorac Surg. 2002 May;73(5):1567-71. doi: 10.1016/s0003-4975(02)03458-6. PubMed 12022551 ↗
  • Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 Oct 17;6:35448. doi: 10.1038/srep35448. PubMed 27748430 ↗
  • Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24. PubMed 19934295 ↗

Individual participant data

Plan to share: Yes — General Data Protection Regulation (GDPR) and HIPPA privacy laws will be followed for sharing of any data.

Supporting information: Study protocol, Informed consent form

Time frame: During the study for a period of 4 years.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2027, 42 months after the start.

Of 24 phase 3 interventional studies under Sarcoma, half reached primary completion within 105 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 155. This study's planned 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Feb 16, 2024
StartActual
Jun 28, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. 10 sites changed recruiting status (10 now active, not recruiting)
Show 10 sites
  • Sarcoma Oncology Center · Santa Monica, United StatesRecruiting→Active, not recruiting
  • Yale School of Medicine - Smilow Cancer Hospital - Yale - New Haven Hospital Location · New Haven, United StatesRecruiting→Active, not recruiting
  • Profound Research LLC · Farmington Hills, United StatesRecruiting→Active, not recruiting
  • Princess Margaret Cancer Centre · Toronto, CanadaRecruiting→Active, not recruiting
  • Centre Leon Berard · Lyon, FranceRecruiting→Active, not recruiting
  • Helios Klinikum Bad Saarow · Bad Saarow, GermanyRecruiting→Active, not recruiting
  • Universitäres Krebszentrum (UCCL) · Leipzig, GermanyRecruiting→Active, not recruiting
  • Hospital de la Santa Creu i Sant Pau · Barcelona, SpainRecruiting→Active, not recruiting
  • Hospital Universitari Vall Hebron · Barcelona, SpainRecruiting→Active, not recruiting
  • Centro Integral Oncologico Clara Campal (HM CIOCC) · Madrid, SpainRecruiting→Active, not recruiting
Show 3 added (3 United States)
  • Mayo Clinic - Arizona · Phoenix, United States
  • Mayo Clinic - Florida · Jacksonville, United States
  • Mayo Clinic - Rochester I · Rochester, United States
Nov 17, 2026
Site contacts
Changed at 12 sites. See the sites
Show 12 sites
  • USC/Norris Comprehensive Cancer Center · Los Angeles, United StatesContact person changed (no phone or email listed)
  • Sarcoma Oncology Center · Santa Monica, United StatesContact removed S•••@gmail.com · •••5391Contact removed (no phone or email listed)
  • Yale School of Medicine - Smilow Cancer Hospital - Yale - New Haven Hospital Location · New Haven, United StatesContact removed l•••@yale.edu · •••4635Contact removed (no phone or email listed)
  • Profound Research LLC · Farmington Hills, United StatesContact removed i•••@profounresearch.io · •••0552Contact removed (no phone or email listed)
  • Duke Cancer Center · Durham, United StatesContact r•••@duke.edu · •••6932→J•••@duke.edu · •••5550Contact person changed (no phone or email listed)
  • Princess Margaret Cancer Centre · Toronto, CanadaContact removed g•••@uhnn.ca · •••8298Contact removed (no phone or email listed)
  • Centre Leon Berard · Lyon, FranceContact removed p•••@lyon.unicancer.fr · •••2828Contact removed (no phone or email listed)
  • Helios Klinikum Bad Saarow · Bad Saarow, GermanyContact removed s•••@helios-gesundheit.de · •••3728Contact removed (no phone or email listed)
  • Universitäres Krebszentrum (UCCL) · Leipzig, GermanyContact removed C•••@medizin.uni-leipzig.de · •••0037Contact removed (no phone or email listed)
  • Hospital de la Santa Creu i Sant Pau · Barcelona, SpainContact removed R•••@santpau.cat · •••1167Contact removed (no phone or email listed)
  • Hospital Universitari Vall Hebron · Barcelona, SpainContact removed C•••@vhio.netContact removed (no phone or email listed)
  • Centro Integral Oncologico Clara Campal (HM CIOCC) · Madrid, SpainContact removed e•••@hmhospitales.com · •••7850Contact removed (no phone or email listed)
Nov 17, 2026
Sponsor
Collaborators added: OPIS USA; collaborators removed: Premier Research
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    3 sites added. 10 sites changed recruiting status (10 now active, not recruiting)
    Show 10 sites
    • Sarcoma Oncology Center · Santa Monica, United StatesRecruiting→Active, not recruiting
    • Yale School of Medicine - Smilow Cancer Hospital - Yale - New Haven Hospital Location · New Haven, United StatesRecruiting→Active, not recruiting
    • Profound Research LLC · Farmington Hills, United StatesRecruiting→Active, not recruiting
    • Princess Margaret Cancer Centre · Toronto, CanadaRecruiting→Active, not recruiting
    • Centre Leon Berard · Lyon, FranceRecruiting→Active, not recruiting
    • Helios Klinikum Bad Saarow · Bad Saarow, GermanyRecruiting→Active, not recruiting
    • Universitäres Krebszentrum (UCCL) · Leipzig, GermanyRecruiting→Active, not recruiting
    • Hospital de la Santa Creu i Sant Pau · Barcelona, SpainRecruiting→Active, not recruiting
    • Hospital Universitari Vall Hebron · Barcelona, SpainRecruiting→Active, not recruiting
    • Centro Integral Oncologico Clara Campal (HM CIOCC) · Madrid, SpainRecruiting→Active, not recruiting
    Show 3 added (3 United States)
    • Mayo Clinic - Arizona · Phoenix, United States
    • Mayo Clinic - Florida · Jacksonville, United States
    • Mayo Clinic - Rochester I · Rochester, United States
    Sponsor Collaborators added: OPIS USA; collaborators removed: Premier Research
    Site contacts Changed at 12 sites. See the sites
    Show 12 sites
    • USC/Norris Comprehensive Cancer Center · Los Angeles, United StatesContact person changed (no phone or email listed)
    • Sarcoma Oncology Center · Santa Monica, United StatesContact removed S•••@gmail.com · •••5391Contact removed (no phone or email listed)
    • Yale School of Medicine - Smilow Cancer Hospital - Yale - New Haven Hospital Location · New Haven, United StatesContact removed l•••@yale.edu · •••4635Contact removed (no phone or email listed)
    • Profound Research LLC · Farmington Hills, United StatesContact removed i•••@profounresearch.io · •••0552Contact removed (no phone or email listed)
    • Duke Cancer Center · Durham, United StatesContact r•••@duke.edu · •••6932→J•••@duke.edu · •••5550Contact person changed (no phone or email listed)
    • Princess Margaret Cancer Centre · Toronto, CanadaContact removed g•••@uhnn.ca · •••8298Contact removed (no phone or email listed)
    • Centre Leon Berard · Lyon, FranceContact removed p•••@lyon.unicancer.fr · •••2828Contact removed (no phone or email listed)
    • Helios Klinikum Bad Saarow · Bad Saarow, GermanyContact removed s•••@helios-gesundheit.de · •••3728Contact removed (no phone or email listed)
    • Universitäres Krebszentrum (UCCL) · Leipzig, GermanyContact removed C•••@medizin.uni-leipzig.de · •••0037Contact removed (no phone or email listed)
    • Hospital de la Santa Creu i Sant Pau · Barcelona, SpainContact removed R•••@santpau.cat · •••1167Contact removed (no phone or email listed)
    • Hospital Universitari Vall Hebron · Barcelona, SpainContact removed C•••@vhio.netContact removed (no phone or email listed)
    • Centro Integral Oncologico Clara Campal (HM CIOCC) · Madrid, SpainContact removed e•••@hmhospitales.com · •••7850Contact removed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06263231
Lead sponsor
Intensity Therapeutics, Inc.
Collaborators
OPIS USA
Responsible party
Sponsor
First posted
Feb 16, 2024
Start date
Jun 28, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Kimberly Guedes, RN, M.B.A
Contact
KGuedes@intensitytherapeutics.com
(203) 293-4224
Lewis H Bender, MS, MA, MBA
Contact
LBender@intensityTherapeutics.com
(203) 221-7377
Christian F. Meyer, MD, PhD, MS
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6

Start the discussion